KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Finished Goods (2016 - 2018)

Historic Finished Goods for Travere Therapeutics (TVTX) over the last 4 years, with Q1 2018 value amounting to $1.4 million.

  • Travere Therapeutics' Finished Goods fell 1117.46% to $1.4 million in Q1 2018 from the same period last year, while for Mar 2018 it was $1.4 million, marking a year-over-year decrease of 1117.46%. This contributed to the annual value of $1.9 million for FY2017, which is 2859.06% up from last year.
  • According to the latest figures from Q1 2018, Travere Therapeutics' Finished Goods is $1.4 million, which was down 1117.46% from $1.9 million recorded in Q4 2017.
  • Travere Therapeutics' 5-year Finished Goods high stood at $2.5 million for Q2 2016, and its period low was $1.4 million during Q1 2018.
  • For the 4-year period, Travere Therapeutics' Finished Goods averaged around $1.9 million, with its median value being $1.7 million (2017).
  • As far as peak fluctuations go, Travere Therapeutics' Finished Goods crashed by 3368.94% in 2016, and later surged by 2859.06% in 2017.
  • Quarter analysis of 4 years shows Travere Therapeutics' Finished Goods stood at $2.2 million in 2015, then crashed by 33.69% to $1.5 million in 2016, then rose by 28.59% to $1.9 million in 2017, then fell by 26.98% to $1.4 million in 2018.
  • Its Finished Goods was $1.4 million in Q1 2018, compared to $1.9 million in Q4 2017 and $1.6 million in Q1 2017.